恰加斯病疫苗的专利情况表明，对这一正在出现的全球健康威胁的投资严重不足

IF 41.7 1区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature biotechnology Pub Date : 2025-08-12 DOI:10.1038/s41587-025-02759-w

Lily Widdup, Bradley Johnson, Stanley P. Kowalski

引用次数: 0

摘要

考虑到南美锥虫病对人类和经济造成的巨大损失，对诊断、药品和疫苗等医疗创新的研发投资仍然低得不成比例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

The patent landscape of Chagas disease vaccines indicates major underinvestment in an emerging global health threat

查看原文本刊更多论文

The patent landscape of Chagas disease vaccines indicates major underinvestment in an emerging global health threat

Considering the enormous human and economic toll Chagas disease inflicts, investment in R&D of medical innovations such as diagnostics, pharmaceuticals and vaccines remains disproportionately low.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature biotechnology 工程技术-生物工程与应用微生物

CiteScore

63.00

自引率

1.70%

发文量

382

审稿时长

3 months

期刊介绍： Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research. The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field. Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology. In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.